Ten-year follow-up shows efficacy of Sanofi's MS drug Lemtrada
New data from a 10-year follow-up study showing the effectiveness of Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (MS) has been presented by French pharma major Sanofi (Euronext: SAN).
The company’s specialty care global business unit, Sanofi Genzyme, presented results from the ongoing, long-term extension study of the Phase II CAMMS223 trial at the 68th American Academy of Neurology (AAN) 2016 Annual Meeting in Vancouver, Canada.
Results showed that 76% of patients were free from six-month confirmed disability worsening and 78% had an expanded disability status scale (EDSS) score that was either stable or showed greater than or equal to a one point improvement in EDSS against the baseline figure. In addition, a low annualized relapse rate was maintained over the period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze